89 search results for Estrogen
| # | SuperPathway Name | Genes Count | Relevance Score | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Validated nuclear estrogen receptor alpha network | 65 | 1.984 | |||||||
|
||||||||||
| 2 | MNAR-PELP1 and Estrogen Receptor Interaction | 23 | 1.753 | |||||||
|
||||||||||
| 3 | Estrogen signaling pathway | 23 | 1.753 | |||||||
|
||||||||||
| 4 | Plasma membrane estrogen receptor signaling | 24 | 1.753 | |||||||
|
||||||||||
| 5 | Validated nuclear estrogen receptor beta network | 15 | 1.589 | |||||||
|
||||||||||
| 6 | Estrogen receptor pathway | 13 | 1.589 | |||||||
|
||||||||||
| 7 | ESR-mediated signaling | 298 | 1.585 | |||||||
|
||||||||||
| 8 | Estrogen metabolism | 23 | 1.427 | |||||||
|
||||||||||
| 9 | Chks in Checkpoint Regulation | 186 | 1.121 | |||||||
|
||||||||||
| 10 | Development Dopamine D2 receptor transactivation of EGFR | 128 | 1.121 | |||||||
|
||||||||||
| 11 | GPCR Pathway | 712 | 1.121 | |||||||
|
||||||||||
| 12 | Gene expression (Transcription) | 1546 | 0.884 | |||||||
|
||||||||||
| 13 | Nuclear receptors | 63 | 0.884 | |||||||
|
||||||||||
| 14 | Signal Transduction | 2590 | 0.884 | |||||||
|
||||||||||
| 15 | Metabolism of steroid hormones | 35 | 0.562 | |||||||
|
||||||||||
| 16 | Signaling by Overexpressed Wild-Type EGFR in Cancer | 24 | 0.562 | |||||||
|
||||||||||
| 17 | Estrone metabolism | 24 | 0.562 | |||||||
|
||||||||||
| 18 | Prolactin Signaling | 432 | 0.562 | |||||||
|
||||||||||
| 19 | PIP3 activates AKT signaling | 310 | 0.559 | |||||||
|
||||||||||
| 20 | Breast cancer pathway | 199 | 0.559 | |||||||
|
||||||||||
| 21 | TGF-beta Signaling Pathways | 96 | 0.559 | |||||||
|
||||||||||
| 22 | Nanog in Mammalian ESC Pluripotency | 534 | 0.559 | |||||||
|
||||||||||
| 23 | MAPK-Erk Pathway | 275 | 0.559 | |||||||
|
||||||||||
| 24 | Female steroid hormones in cardiomyocyte energy metabolism | 9 | 0.559 | |||||||
|
||||||||||
| 25 | ERK Signaling | 1185 | 0.559 | |||||||
|
||||||||||
| 26 | 11p11.2 copy number variation syndrome | 144 | 0.559 | |||||||
|
||||||||||
| 27 | Primary ovarian insufficiency | 170 | 0.559 | |||||||
|
||||||||||
| 28 | Oxysterols derived from cholesterol | 36 | 0.559 | |||||||
|
||||||||||
| 29 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 135 | 0.559 | |||||||
|
||||||||||
| 30 | RNA Polymerase II Transcription Initiation And Promoter Clearance | 205 | 0.559 | |||||||
|
||||||||||
| 31 | Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics | 4 | 0.559 | |||||||
|
||||||||||
| 32 | Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) | 32 | 0.559 | |||||||
|
||||||||||
| 33 | Apoptosis and survival_Anti-apoptotic action of nuclear ESR1 and ESR2 | 28 | 0.559 | |||||||
|
||||||||||
| 34 | Development Ligand-independent activation of ESR1 and ESR2 | 135 | 0.559 | |||||||
|
||||||||||
| 35 | Regulation of activated PAK-2p34 by proteasome mediated degradation | 978 | 0.559 | |||||||
|
||||||||||
| 36 | RAF/MAP kinase cascade | 571 | 0.559 | |||||||
|
||||||||||
| 37 | Infectious disease | 1747 | 0.559 | |||||||
|
||||||||||
| 38 | GDNF signaling | 132 | 0.395 | |||||||
|
||||||||||
| 39 | Transport of the SLBP independent Mature mRNA | 285 | 0.395 | |||||||
|
||||||||||
| 40 | 16p11.2 proximal deletion syndrome | 72 | 0.395 | |||||||
|
||||||||||
| 41 | Development VEGF signaling via VEGFR2 - generic cascades | 147 | 0.395 | |||||||
|
||||||||||
| 42 | Signaling events mediated by HDAC Class I | 118 | 0.395 | |||||||
|
||||||||||
| 43 | Signaling mediated by p38-alpha and p38-beta | 33 | 0.395 | |||||||
|
||||||||||
| 44 | Mammary gland development pathway - Puberty (Stage 2 of 4) | 13 | 0.395 | |||||||
|
||||||||||
| 45 | Signaling by Receptor Tyrosine Kinases | 524 | 0.395 | |||||||
|
||||||||||
| 46 | LKB1 signaling events | 37 | 0.395 | |||||||
|
||||||||||
| 47 | Cellular roles of Anthrax toxin | 19 | 0.395 | |||||||
|
||||||||||
| 48 | FOXM1 transcription factor network | 36 | 0.395 | |||||||
|
||||||||||
| 49 | CCL18 signaling pathway | 96 | 0.395 | |||||||
|
||||||||||
| 50 | Ovarian infertility | 36 | 0.395 | |||||||
|
||||||||||
| 51 | Transcription Ligand-dependent activation of the ESR1/SP pathway | 51 | 0.395 | |||||||
|
||||||||||
| 52 | Hepatocyte growth factor receptor signaling | 115 | 0.395 | |||||||
|
||||||||||
| 53 | MIF Mediated Glucocorticoid Regulation | 681 | 0.395 | |||||||
|
||||||||||
| 54 | Nuclear receptors meta-pathway | 315 | 0.395 | |||||||
|
||||||||||
| 55 | Energy metabolism | 47 | 0.395 | |||||||
|
||||||||||
| 56 | Deubiquitination | 298 | 0.395 | |||||||
|
||||||||||
| 57 | RUNX1 regulates transcription of genes involved in WNT signaling | 6 | 0.395 | |||||||
|
||||||||||
| 58 | AP-1 transcription factor network | 69 | 0.395 | |||||||
|
||||||||||
| 59 | FOXA1 transcription factor network | 37 | 0.395 | |||||||
|
||||||||||
| 60 | Transcriptional activation of mitochondrial biogenesis | 95 | 0.395 | |||||||
|
||||||||||
| 61 | Ovarian tumor domain proteases | 39 | 0.395 | |||||||
|
||||||||||
| 62 | Estradiol regulation in porto-sinusoidal vascular disease | 7 | 0.395 | |||||||
|
||||||||||
| 63 | CKAP4 signaling pathway map | 108 | 0.395 | |||||||
|
||||||||||
| 64 | Translational Control | 190 | 0.395 | |||||||
|
||||||||||
| 65 | PPARA activates gene expression | 145 | 0.395 | |||||||
|
||||||||||
| 66 | Metabolism of proteins | 1970 | 0.395 | |||||||
|
||||||||||
| 67 | Ectoderm differentiation | 141 | 0.395 | |||||||
|
||||||||||
| 68 | Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 38 | 0.395 | |||||||
|
||||||||||
| 69 | Organelle biogenesis and maintenance | 296 | 0.395 | |||||||
|
||||||||||
| 70 | ncRNAs involved in Wnt signaling in hepatocellular carcinoma | 220 | 0.395 | |||||||
|
||||||||||
| 71 | Integrated breast cancer pathway | 150 | 0.395 | |||||||
|
||||||||||
| 72 | GPCR downstream signalling | 710 | 0.395 | |||||||
|
||||||||||
| 73 | Signaling by ERBB4 | 70 | 0.395 | |||||||
|
||||||||||
| 74 | Class A/1 (Rhodopsin-like receptors) | 556 | 0.395 | |||||||
|
||||||||||
| 75 | Metabolism | 2121 | 0.395 | |||||||
|
||||||||||
| 76 | Glucose / Energy Metabolism | 307 | 0.395 | |||||||
|
||||||||||
| 77 | Regulation of Telomerase | 68 | 0.395 | |||||||
|
||||||||||
| 78 | Genetic causes of porto-sinusoidal vascular disease | 36 | 0.395 | |||||||
|
||||||||||
| 79 | ATF-2 transcription factor network | 57 | 0.395 | |||||||
|
||||||||||
| 80 | Sudden infant death syndrome (SIDS) susceptibility pathways | 159 | 0.395 | |||||||
|
||||||||||
| 81 | Regulation of nuclear SMAD2/3 signaling | 74 | 0.395 | |||||||
|
||||||||||
| 82 | Pre-implantation embryo | 58 | 0.395 | |||||||
|
||||||||||
| 83 | Lamotrigine Pathway, Pharmacokinetics and Pharmacodynamics | 15 | 0.395 | |||||||
|
||||||||||
| 84 | Assembly of the pre-replicative complex | 316 | 0.395 | |||||||
|
||||||||||
| 85 | G alpha (s) signalling events | 158 | 0.395 | |||||||
|
||||||||||
| 86 | Cell cycle Regulation of G1/S transition (part 1) | 124 | 0.395 | |||||||
|
||||||||||
| 87 | ADORA2B mediated anti-inflammatory cytokines production | 419 | 0.395 | |||||||
|
||||||||||
| 88 | 1p36 copy number variation syndrome | 88 | 0.395 | |||||||
|
||||||||||
| 89 | AHR Pathway | 25 | 0.395 | |||||||
|
||||||||||